Estándar de tratamiento en primera línea de cáncer de páncreas metastásico: ¿ABRAXANE-GEMCITABINA o FOLFIRINOX? - page 15

Overall survival

Braiteh F, ASCO GI 2016. P 433

G-CSF profiláctico 8%

39%

Edad (media) 67 años

61 años

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,5,6,7,8,9,10,11,12,13,14 16,17,18,19,20,21,22